Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-5,page-paged-5,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.5.0,vc_responsive

CLIENT NEWS

 

 

  • Marinomed Biotech AG announces positive data demonstrating Carragelose efficacy against SARS-CoV-2 variants
    www.marinomed.com
  • ADOCIA Announces First Quarter 2021 Financial Results
    www.adocia.com
  • XPhyto Signs German Distribution, Storage and Logistics Agreement for 25-Minute COVID-19 PCR Test
    www.xphyto.com
  • Abivax Hosting Key Opinion Leader Webinar on ABX464 for the Treatment of Ulcerative Colitis
    www.abivax.com
  • Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp.
    www.relieftherapeutics.com
  • Relief Reports 2020 Financial Results and Provides Business Update
    www.relieftherapeutics.com
  • Abivax completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis
    www.abivax.com
  • Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal “Gastroenterology”
    www.abivax.com
  • Newron announces AGM 2021 result
    www.newron.com
  • LINDIS Biotech Reports Successful Initiation of Clinical Phase I Dose Escalation Study with the Trifunctional Antibody CATUMAXOMAB for Treatment of Non-Muscle-Invasive Bladder Cancer
    www.lindisbiotech.com